Related Experiment Video

Updated: Jul 2, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation

Ruriko Tanaka1, Shinya Kimura

  • 1Department of Transfusion Medicine & Cell Therapy, Kyoto University Hospital, 54 Kawahara Sakyo-ku Kyoto 606-8507, Japan. ruri@kuhp.kyoto-u.ac.jp

Expert Review of Anticancer Therapy
|September 2, 2008
PubMed

Insights

Chronic myeloid leukemia (CML) treatment advanced with imatinib, but resistance emerged. New Abl TKIs target mutations, yet the T315I mutation remains a challenge, necessitating novel therapeutic strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Chronic myeloid leukemia (CML) treatment revolutionized by imatinib mesylate, an Abl tyrosine kinase inhibitor (TKI).
  • Resistance to imatinib, particularly in advanced CML, is a significant clinical challenge.
  • Abl kinase domain point mutations are the primary cause of imatinib resistance.

Purpose of the Study:

  • To review the current landscape of novel agents for CML treatment.
  • To discuss the efficacy and limitations of existing Abl TKIs against specific mutations.
  • To highlight the unmet need for agents effective against the T315I mutation.

Main Methods:

  • Review of existing literature on CML pathogenesis and treatment.
  • Analysis of the mechanisms of resistance to imatinib and second-generation Abl TKIs.
  • Evaluation of novel agents and strategies targeting T315I mutations.

Main Results:

  • Second-generation Abl TKIs (dasatinib, nilotinib, bosutinib, INNO-406) show promise but do not effectively target the T315I mutation.
  • The T315I mutation confers resistance to all currently approved ATP-competitive Abl TKIs.
  • Development of novel agents is crucial for overcoming T315I-mediated resistance.

Conclusions:

  • The T315I mutation represents a critical barrier in CML treatment.
  • Novel therapeutic strategies are urgently needed to effectively treat CML patients with the T315I mutation.
  • Continued research into new agents is essential for improving outcomes in resistant CML.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...